Athira Pharma prices IPO at $17, sells 12M shares to raise $204M; will trade as ATHA on Nasdaq

Seattle biotech Athira Pharma priced its IPO at $17 per share, selling 12 million shares to raise at least $204 million and will begin trading on Nasdaq under ticker ATHA; the company is developing NDX-1017 for neurodegenerative diseases and has no commercial products yet. Founded in 2011 and led by CEO Dr. Leen Kawas, Athira reported net losses in 2019 and H1 2020 and has raised over $100 million privately, including an $85 million Series B.